Primary Cns Lymphoma clinical trials

Explore recruiting primary cns lymphoma clinical trials.

Recruiting primary cns lymphoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Cns Lymphoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pilot-trial of methotrexate, tafasitamab (Minjuvi®), lenalidomide (Revlimid®) and rituximab in patients ineligible for HCT-ASCT with primary central nervous system lymphoma (PCNSL) -MTR²

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Evaluation of the safety and efficacy of Berubicin in the treatment of central nervous system lymphomas- BERUBICIN

Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Optimizing MATRix as remission induction in PCNSL: De-escalated induction treatment in newly diagnosed primary CNS lymphoma – a randomized phase III trial

Austria, Italy, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a randomized phase III trial - PRIMA-CNS

Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

e-REVRI - A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated with Lenalidomide and Rituximab

France

Phase II and Phase III (Integrated) EU CTIS Study details

Primary Cns Lymphoma trials by city

Primary Cns Lymphoma in Toronto Primary Cns Lymphoma in Vancouver Primary Cns Lymphoma in Montreal Primary Cns Lymphoma in Calgary Primary Cns Lymphoma in Edmonton Primary Cns Lymphoma in Ottawa Primary Cns Lymphoma in Winnipeg Primary Cns Lymphoma in Quebec City Primary Cns Lymphoma in Hamilton Primary Cns Lymphoma in Kitchener Primary Cns Lymphoma in London Primary Cns Lymphoma in Halifax Primary Cns Lymphoma in New York Primary Cns Lymphoma in Los Angeles Primary Cns Lymphoma in Chicago Primary Cns Lymphoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease